ACA
JSPR icon

Acorn Capital Advisors’s Jasper Therapeutics JSPR Stock Holding History

Acorn Capital Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$604K Buy
1,438,159
+26,667
+2% +$20K 0.16% 18
2026
Q1 		$1.24M Sell
1,411,492
-375,000
-21% -$521K 0.35% 19
2025
Q4 		$3.27M Buy
1,786,492
+403,852
+29% +$811K 1.11% 14
2025
Q3 		$3.29M Buy
+1,382,640
New +$4.19M 1.67% 15

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acorn Capital Advisors's JSPR Position: Q2 2026 in Review

Acorn Capital Advisors increased its Jasper Therapeutics (JSPR) stake by 1.9% in Q2 2026, buying an estimated $20K and bringing the position to 1,438,159 shares worth $604K. The position accounts for 0.16% of the portfolio, ranked #18.

Acorn Capital Advisors first reported a position in JSPR in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.29M in Q3 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Acorn Capital Advisors held 1,438,159 shares of Jasper Therapeutics worth $604K as of Q2 2026.
  • Acorn Capital Advisors bought 26,667 Jasper Therapeutics shares in Q2 2026, an estimated $20K.
  • Jasper Therapeutics made up 0.16% of Acorn Capital Advisors's portfolio in Q2 2026, its #18 holding.
  • Acorn Capital Advisors first reported a position in Jasper Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Acorn Capital Advisors's Jasper Therapeutics position peaked at $3.29M in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.